AI won’t eliminate antibody discovery wet-lab workflows. However, high-throughput clean empirical discovery plus ML-driven iterations have the potential to make discovery more predictable, faster to converge, and easier to scale. Read more

Antibody–drug conjugates (ADCs) remain one of the most promising modalities in oncology, but the next generation demands smarter, more adaptable scaffolds. Single-domain antibodies bring precisely that: offering high affinity and stability in a compact, engineerable scaffold. By merging these two platforms, we get an antibody framework that can address long-standing bottlenecks in the industry. Read more

A technical overview of how in vitro discovery platforms support VHH antibody and peptide discovery across challenging protein classes, from soluble enzymes to membrane proteins, toxic antigens and complex multimeric targets, using tailored antigen presentation strategies. Read more

VHH antibodies provide modular, high-performance components that can enhance biologics across multiple modalities. From albumin-binding half-life extension to bi-/multi-specific engineering and intracellular TPD, VHH bolt-ons enable more flexible, efficient and targeted therapeutic design. This article examines the key applications, design considerations e case studies that illustrate how VHH domains support next-generation engineered biologics. Read more

Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on their underlying techniques, important benefits, and suitable applications. Read more